Together, these data suggest that reduced efficacy of anti-PD1 treatment in the younger relative to the elderly group may be attributed to insufficient tumor antigenicity via reduced TMB, the unavailability of readily presentable tumor antigens, or even through the loss of MHC molecules, and increased frequencies of potent Tregs. This evidence concerns the gene HLA-C and neoplasm.